Cite
SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
MLA
Youssef El-Ahmad, et al. “SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.” Molecular Cancer Therapeutics, vol. 20, no. 2, May 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9a793f8b26300e48375f0775740c17d0&authtype=sso&custid=ns315887.
APA
Youssef El-Ahmad, Hong Cheng, Fabienne Thompson, Monsif Bouaboula, Jack Pollard, Gary Mccort, Andrew Hebert, Carlos Garcia-Echeverria, Michel Tabart, Fangxian Sun, Laurent Schio, Joon Sang Lee, Dinesh S. Bangari, Jane Cheng, Laurent Besret, Hui Cao, Dietmar Hoffmann, Maysoun Shomali, Rosalia Arrebola, … Pierre-Yves Abecassis. (2020). SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. Molecular Cancer Therapeutics, 20(2).
Chicago
Youssef El-Ahmad, Hong Cheng, Fabienne Thompson, Monsif Bouaboula, Jack Pollard, Gary Mccort, Andrew Hebert, et al. 2020. “SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.” Molecular Cancer Therapeutics 20 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9a793f8b26300e48375f0775740c17d0&authtype=sso&custid=ns315887.